← All trials
NCT06841003
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Mar 31, 2027
- Completion date
- May 31, 2027
- First posted
- Feb 21, 2025
- Last posted
- Feb 21, 2025
- Enrollment
- 752
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spaarne GasthuisLead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.